Magovcevic-Liebisch Ivana — SEC insider filings
SEC reporting owner CIK 1279281. 24 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2020-12-18 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 5 filings — 24,000 shares, $61,829 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: purchase of 4,000 shares @ $3.75 ($15,000) in Vigil Neuroscience, Inc., filed 2023-11-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vigil Neuroscience, Inc. (VIGL) | President and CEO, Director | 11 | 6 legs · 24,000 sh · $61,829 | — | 17 |
| Quanterix Corp (QTRX) | Director | 3 | — | — | 5 |
| Acrivon Therapeutics, Inc. (ACRV) | Director | 4 | — | — | 4 |
| Aeglea BioTherapeutics, Inc. (AGLE) | Director | 3 | — | — | 3 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) | Director | 2 | — | — | 2 |
| Absci Corp (ABSI) | Director | 1 | — | — | 1 |
Insider filings — Magovcevic-Liebisch Ivana
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Quanterix Corp (QTRX) | Option exercise (M): 4,224 · Option exercise (M): 4,224 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-01-15 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 23,372 @ $0 | EDGAR |
| 2025-08-05 | 4 | Vigil Neuroscience, Inc. (VIGL) | Disposition to issuer (D): 222,687 · Disposition to issuer (D): 369,351 (derivative) · Disposition to issuer (D): 210,629 (derivative) · Disposition to issuer (D): 405,494 (derivative) · Disposition to issuer (D): 43,271 (derivative) · Disposition to issuer (D): 282,000 (derivative) · +3 more | EDGAR |
| 2025-06-17 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Vigil Neuroscience, Inc. (VIGL) | Grant/award (A): 485,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Vigil Neuroscience, Inc. (VIGL) | Purchase (P): 5,000 @ $1.68 | EDGAR |
| 2024-12-18 | 4 | Vigil Neuroscience, Inc. (VIGL) | Purchase (P): 5,000 @ $1.67 | EDGAR |
| 2024-12-05 | 4 | Vigil Neuroscience, Inc. (VIGL) | Purchase (P): 5,000 @ $2.34 | EDGAR |
| 2024-10-03 | 4 | Quanterix Corp (QTRX) | Grant/award (A): 12,800 @ $0 · Grant/award (A): 27,689 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Vigil Neuroscience, Inc. (VIGL) | Disposition to issuer (D): 282,000 (derivative) @ $0 · Grant/award (A): 282,000 (derivative) @ $0 · Disposition to issuer (D): 370,000 (derivative) @ $0 · Grant/award (A): 370,000 (derivative) @ $0 | EDGAR |
| 2024-03-01 | 4 | Vigil Neuroscience, Inc. (VIGL) | Grant/award (A): 463,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2023-11-20 | 4 | Vigil Neuroscience, Inc. (VIGL) | Purchase (P): 4,000 @ $3.75 | EDGAR |
| 2023-06-30 | 4 | Aeglea BioTherapeutics, Inc. (AGLE) | Grant/award (A): 1,950,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Vigil Neuroscience, Inc. (VIGL) | Grant/award (A): 370,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Absci Corp (ABSI) | Grant/award (A): 28,700 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | Aeglea BioTherapeutics, Inc. (AGLE) | Grant/award (A): 43,000 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Vigil Neuroscience, Inc. (VIGL) | Purchase (P): 4,000 @ $3.61 · Purchase (P): 1,000 @ $3.94 | EDGAR |
| 2022-03-03 | 4 | Vigil Neuroscience, Inc. (VIGL) | Grant/award (A): 282,000 (derivative) @ $0 | EDGAR |
| 2021-12-02 | 4 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2021-06-09 | 4 | Aeglea BioTherapeutics, Inc. (AGLE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2020-12-18 | 4 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1279281 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs